Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: Emphasis on an apparent fraction unbound in liver for drugs

Journal of Pharmaceutical Sciences

Volumn 102, Issue 7, 2013, Pages 2085-2095

  Poulin, Patrick ^a  

^a Québec city   (Canada)

Author keywords

Hepatocytes; in vitro in vivo correlation; in vitro in vivo extrapolation; Intrinsic clearance; IVIVE; Metabolism; PBPK modeling; Permeability; Pharmacokinetics; Physiologically based pharmacokinetics; Transport; Unbound fraction

Indexed keywords

ALBUMIN; ALISKIREN; ATORVASTATIN; BOSENTAN; CERIVASTATIN; CIPROFLOXACIN; CYCLOSPORIN; DIGOXIN; FEXOFENADINE; FLUINDOSTATIN; FUROSEMIDE; INDOMETACIN; KETOCONAZOLE; NAPSAGATRAN; PENICILLIN G; PITAVASTATIN; PRAVASTATIN; PROPRANOLOL; QUINIDINE; REPAGLINIDE; ROSUVASTATIN; VALSARTAN; VERAPAMIL;

ACIDITY; ANIMAL CELL; ARTICLE; DRUG BINDING; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO TO IN VIVO EXTRAPOLATION; IONIZATION; LIVER CELL; LIVER CLEARANCE; MICROSOME; NONHUMAN; PERFORMANCE; RAT;

EID: 84879018695     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23562     Document Type: Article

References (35)

1. Poulin P, Kenny JR, Hop ECA, Haddad S. 2012. In vitro-in vivo extrapolation of clearance: Modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing methods. J Pharm Sci 101:838-851.
2. Poulin P, Hop ECJ, Haddad S, Kenny JT. 2012. Comparative assessment of in vitro--in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101:4308-4326.
3. Poulin P, Haddad S. 2013. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. J Pharm Sci. [Epub ahead of print. DOI: 10.1002/jps.23502].
4. Burczynski FJ, Wang GQ, Elmhadoun B, She YM, Roberts MS, Standing KG. 2001. Hepatocyte palmitate uptake: Effect of albumin surface charge modification. Can J Physiol Pharmacol 79:868-875.
5. Burczynski FJ, Wang GQ, Hnatowich M. 1997. Effect of binding protein surface charge on palmitate uptake by hepatocyte suspensions. Br J Pharmacol 120:1215-1220.
6. Mariappan TT, Mandlekar S, Marathe P. 2013. Insight into tissue unbound concentration: Utility in drug discovery and development. Curr Drug Metab 14:324-340.
7. Halifax D, Houston BJ. 2012. Evaluation of hepatic clearance prediction using in vitro data: Emphasis of fraction unbound in plasma and drug ionization using a dataset of 107 drugs. J Pharm Sci 101:2645-2652.
8. Sohlenius-Sternbeck AK, Fagerholm U, Bylund J. 2013. The volume of distribution is an indicator of poor in vitro-in vivo extrapolation of clearance for acidic drugs in the rat. Xenobiotica. [Epub ahead of print. DOI:10.3109/00498254.2012.755578].
9. Umehara K, Camenisch G. 2012. Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Pharm Res 29:603-617.
10. Umehara K, Camenisch G. 2012. Predicting human hepatic clearance from in vitro drug metabolism and transport data: A scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos 33:179-194.
11. Sohlenius-Sternbeck AK, Jones C, Ferguson D, Middleton BJ, Projean D, Floby E, Bylund J, Afzelius L. 2012. Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841-953.
12. Huang L, Chen A, Roberts J, Janosky B, Be X, Berry L, Lin MHJ. 2012. Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds. Xenobiotica 42:830-840.
13. Ménochet K, Kenworthy KE, Houston BJ, Galetin A. 2012. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744-1756.
14. Jones HM, Barton HA, Lai Y, Bi Y, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston BJ, Galetin A, Fenner KS. 2012. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in human from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
15. Poirier A, Funk C, Scherrmann JM, Lavé T. 2009. Mechanistic modeling of hepatic transport from cells to whole Body: Application to Napsagatran and Fexofenadine. Mol Pharm 6:1716-1733.
16. Paine SW, Parker AJ, Gardiner P, Webborn PJH, Riley RJ. 2008. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365-1374.
17. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. 2009. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
18. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y. 2009. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215-222.
19. Ring B, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RDO, Yates JWT, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 3. Comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090-4110.
20. Austin RP, Barton P, Mohmed S, Riley RJ. 2005. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33:419-425
21. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. 2003. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563.
22. Gupta SK, Legg B, Solomon LR, Johnson WG, Rowland M. 1987. Pharmacokinetics of cyclosporin: Influence of rate of constant intravenous infusion in renal transplant patients. Br J Clin Pharmacol 24:519-526.
23. Kawai R, Mathew D, Tanaka C, Rowland M. 1998. Physiologically based pharmacokinetics of cyclosporine A: Extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287:457-468.
24. Poulin P, Theil FP. 2009. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98:4941-4961.
25. Wattanachai N, Polasek TM, Heath TM, Uchaipichat V, Wongwiwat T, Tassaneeyakul W, Miners JO. 2011. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: Effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815-824.
26. Baba T, Touchi A, Ito K, Yamaguchi Y, Yamazoe Y, Ohno Y, Sugiyama Y. 2002. Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metab Pharmacokinet 17:522-531.
27. Zucker SD, Goessling W, Gollan JL. 1995. Kinetics of bilirubin transfer between serum albumin and membrane vesicles. J Biol Chem 270:1074-1081.
28. Tang C, Lin Y, Rodrigues DA, Lin JH. 2002. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: An impact more than protein binding. Drug Metab Dispos 30:648-654.
29. Mitchell SJ, Huizer-Pajkos A, Cogger VC, McLachlan AJ, Le Couteur DG, Jones D, de Cabo R, Hilmer SN. 2012. The influence of old age and poloxamer-407 on the hepatic disposition of diazepam in the isolated perfused rat liver. Pharmacology 90:233-241.
30. Burczynski FJ, Fandrey S, Wang G, Pavletic PA, Gong Y. 1999. Cytosolic fatty acid binding protein enhances rat hepatocyte [3H]palmitate uptake. J Physiol Pharmacol 77:896-901.
31. Gill KL, Houston BJ, Galetin A. 2012. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: Comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metb Dispos 40:825-835.
32. Osterloh K, Ewert U, Pries AR. 2002. Interaction of albumin with the endothelial cell surface. Am J Physiol 283:H398-H405.
33. Sjögren E, Bredberg U, Lennernäs H. 2012. The pharmacokinetics and hepatic disposition of repaglinide in pigs: Mechanistic modeling of metabolism and transport. Mol Pharm 9:823-841.
34. Yabe Y, Galetin A, Houston BJ. 2011. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808-1814.
35. Haddad S, Poulin P, Funk C. 2010. Extrapolating in vitro metabolic interactions to isolated perfused liver: Prediction of metabolic interactions between bufarolol, bunitrolol and debrisoquine. J Pharm Sci 99:4406-4426.